What is the recommended medication regimen, including formulation and dosing, for restarting atomoxetine (Strattera) and escitalopram (Lexapro) in a 9‑year‑old girl with ADHD and depressive symptoms related to bullying who previously could not tolerate the capsule form and experienced stomach discomfort with escitalopram?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 22, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Recommended Medication Regimen for Restarting Atomoxetine and Escitalopram

Restart atomoxetine as an oral solution at 24 mg daily (approximately 1.2 mg/kg/day for a 9-year-old) and restart escitalopram at 5 mg once daily in the morning with breakfast to minimize gastrointestinal side effects.

Atomoxetine (Strattera) Formulation and Dosing

The patient's previous difficulty swallowing capsules necessitates switching to the liquid formulation. Atomoxetine is available as an oral solution at 4 mg/mL 1, 2. The prescribed dose of 24 mg daily can be achieved with 6 mL of the oral solution, administered once daily in the morning.

Dosing Rationale:

  • The target therapeutic dose for atomoxetine in children is 1.2 mg/kg/day, with a maximum of 1.4 mg/kg/day or 100 mg/day, whichever is lower 1
  • For a typical 9-year-old (approximately 20-30 kg), 24 mg represents an appropriate starting maintenance dose
  • Atomoxetine provides "around-the-clock" effects, making once-daily dosing effective throughout the school day and evening 1
  • The liquid formulation eliminates the swallowing difficulty that caused previous non-adherence 2

Monitoring Requirements:

  • Close monitoring for suicidality, clinical worsening, and unusual behavioral changes is mandatory, especially during the first few months and at dose changes 1
  • Monitor pulse and blood pressure at each visit
  • Assess for common adverse effects: nausea, vomiting, decreased appetite, abdominal pain, and somnolence 1
  • Weight and height should be tracked, though growth typically normalizes after 2-3 years 3

Escitalopram Dosing Strategy

Administer escitalopram 5 mg once daily in the morning with breakfast rather than at night to address the previous stomach discomfort issue.

Dosing Rationale:

  • The starting dose of 10 mg for escitalopram in adolescents can be reduced to 5 mg initially for better tolerability 4
  • Taking escitalopram with food in the morning significantly reduces gastrointestinal side effects compared to evening dosing on an empty stomach
  • The effective dose range is 10-20 mg daily, allowing for upward titration if needed 4
  • Escitalopram is FDA-approved for adolescents aged 12 years and older, though this patient is 9 years old, making this off-label use 4

Critical Safety Considerations:

  • Black box warning: Monitor closely for suicidal ideation, especially in the first few weeks of treatment or with dose changes 4
  • Contact should occur within the first week after initiation to assess tolerability and adherence
  • The patient should be seen or contacted by phone weekly during the first month 4

Drug Interaction Consideration

Important caveat: Escitalopram is a CYP2D6 inhibitor and can elevate atomoxetine serum levels 1. This interaction means:

  • The patient may experience higher atomoxetine exposure than expected for the dose
  • Monitor more carefully for atomoxetine-related adverse effects (nausea, decreased appetite, somnolence)
  • The 24 mg dose may need to remain stable longer before any upward titration
  • If adverse effects emerge, consider that they may be related to elevated atomoxetine levels rather than requiring escitalopram discontinuation

Timeline for Assessment

Follow-up schedule:

  • Week 1: Phone contact to assess tolerability, adherence, and emergence of adverse effects
  • Week 2-4: Weekly phone or in-person contact to monitor for suicidality and behavioral changes
  • Month 1: In-person visit to assess efficacy and adjust dosing if needed
  • Atomoxetine requires 6-12 weeks for full therapeutic effect 1, so patience is essential before declaring treatment failure

Addressing Comorbid Depression

The evidence specifically notes that atomoxetine was initially developed as an antidepressant but does not demonstrate efficacy for depressive symptoms 1. However, recent data suggests atomoxetine may improve depressive symptoms in children with ADHD and comorbid mood disorders, though with slower improvement than ADHD symptoms alone 5. The escitalopram addresses the depression directly, which is appropriate given the bullying-related depressive symptoms and family stressors.

Common Pitfalls to Avoid

  • Do not restart at higher doses: The previous 25 mg capsule dose was appropriate, but starting with liquid formulation at 24 mg (slightly lower) allows assessment of tolerability with the new formulation
  • Do not continue evening dosing of escitalopram: The morning-with-food strategy is critical to prevent recurrence of stomach discomfort
  • Do not expect immediate results: Families must understand atomoxetine takes 6-12 weeks for full effect, unlike stimulants which work within hours
  • Do not overlook the CYP2D6 interaction: The combination requires more vigilant monitoring than either medication alone

References

Related Questions

What is the recommended way to increase a child's atomoxetine (Strattera) dose from 18 mg to 25 mg?
For Strattera (atomoxetine) taken at 50 mg daily by mouth, is a taper required when discontinuing?
Can I start atomoxetine (Strattera) on a patient who has been off medication for a long period and was previously treated with stimulant medications for ADHD?
A 6-year-old child taking atomoxetine (Strattera) 50 mg daily is not showing improvement; what is the next step in management?
What is a safe starting dose of atomoxetine (Strattera) for a 14‑year‑old male with ADHD and depression, weighing 50 kg, who cannot tolerate stimulant medications?
What is the appropriate management for a 20‑year‑old woman with a one‑week history of an itchy, purulent rash in the web space between her fingers?
Are there any contraindications to using topical Voltaren (diclofenac) on the neck?
What is the appropriate dosing of glucagon‑like peptide‑1 (GLP‑1) receptor agonists in patients with chronic kidney disease (CKD)?
What are the contraindications to combined oral contraceptive pills for a healthy 19‑year‑old woman who is not pregnant, does not smoke heavily, and has no history of thromboembolic disease, hypertension, migraine with aura, liver disease, or estrogen‑sensitive cancer?
Interpret the laboratory results (follicle‑stimulating hormone 40.6 IU/L, luteinizing hormone 27.5 IU/L, testosterone 14 ng/dL, estradiol 47.5 pg/mL, progesterone 0.3 ng/mL, sex hormone‑binding globulin 64.4 nmol/L) in a 46‑year‑old female with a partial hysterectomy.
For an adult patient with post‑traumatic stress disorder who has been taking gabapentin 100 mg by mouth each morning for about a year without benefit and develops dizziness when the dose is increased, hydroxyzine 50 mg by mouth at bedtime as needed is no longer effective, and is self‑administering magnesium glycinate 100 mg, vitamin D3 2000 IU daily, atomoxetine (Strattera) 40 mg at bedtime, and N‑acetylcysteine 600 mg daily, what medication management changes should be considered?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.